CA3179754A1 - Cyclobenzaprine treatment for sexual dysfunction - Google Patents

Cyclobenzaprine treatment for sexual dysfunction

Info

Publication number
CA3179754A1
CA3179754A1 CA3179754A CA3179754A CA3179754A1 CA 3179754 A1 CA3179754 A1 CA 3179754A1 CA 3179754 A CA3179754 A CA 3179754A CA 3179754 A CA3179754 A CA 3179754A CA 3179754 A1 CA3179754 A1 CA 3179754A1
Authority
CA
Canada
Prior art keywords
cyclobenzaprine
agent
pharmaceutically acceptable
combination
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3179754A
Other languages
English (en)
French (fr)
Inventor
Megan Elizabeth PARMENTER
Gregory M. Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Inc
Original Assignee
Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharmaceuticals Holding Corp, Tonix Pharmaceuticals Inc filed Critical Tonix Pharmaceuticals Holding Corp
Publication of CA3179754A1 publication Critical patent/CA3179754A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3179754A 2020-04-08 2021-04-08 Cyclobenzaprine treatment for sexual dysfunction Pending CA3179754A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063007251P 2020-04-08 2020-04-08
US63/007,251 2020-04-08
PCT/US2021/026492 WO2021207561A1 (en) 2020-04-08 2021-04-08 Cyclobenzaprine treatment for sexual dysfunction

Publications (1)

Publication Number Publication Date
CA3179754A1 true CA3179754A1 (en) 2021-10-14

Family

ID=75675042

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3179754A Pending CA3179754A1 (en) 2020-04-08 2021-04-08 Cyclobenzaprine treatment for sexual dysfunction

Country Status (7)

Country Link
US (1) US20210315841A1 (cg-RX-API-DMAC7.html)
EP (1) EP4132648B1 (cg-RX-API-DMAC7.html)
JP (2) JP7780447B2 (cg-RX-API-DMAC7.html)
CN (1) CN115803088B (cg-RX-API-DMAC7.html)
AU (1) AU2021253592A1 (cg-RX-API-DMAC7.html)
CA (1) CA3179754A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021207561A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240415789A1 (en) * 2021-10-06 2024-12-19 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
US12370198B2 (en) 2022-07-08 2025-07-29 La Pharmatech Inc Pharmaceutical compositions and methods for treating psychiatric disorders
KR20250086333A (ko) * 2023-12-06 2025-06-13 삼진제약주식회사 약학적 제제 및 이의 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
AR025110A1 (es) * 1999-08-13 2002-11-06 Vela Pharmaceuticals Inc Metodos y composiciones para tratar o prevenir alteraciones del sueno y enfermedades asociadas usando dosis muy bajas de ciclobenzaprina
US6855324B2 (en) * 2000-11-20 2005-02-15 Adrian Sandler Therapeutic placebo enhancement of commonly-used medications
JP2008540673A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤誘発性性機能不全の治療方法
PT2501234T (pt) * 2009-11-20 2017-12-13 Tonix Pharma Holdings Ltd Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina
EA201391459A1 (ru) 2011-04-04 2014-03-31 С1 Биофарма, Инк. Режимы лечения
SI2861223T1 (sl) * 2012-06-15 2023-01-31 Tonix Pharma Holdings Limited Sestavki in postopki za transmukozalno absorpcijo
MY196014A (en) * 2013-03-15 2023-03-06 Tonix Pharmaceuticals Inc Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride
SG10201902203VA (en) * 2014-09-18 2019-04-29 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
JP2018512450A (ja) * 2015-03-19 2018-05-17 ウェンディ アン エプスタインEPSTEIN, Wendy Anne 女性の性的障害を治療するための化合物及び剤型
MX2019005851A (es) * 2016-11-22 2019-10-07 Alkalidx Inc Terapias para el tratamiento de afecciones hipocalemicas e ineficaces a lidocaina.
BR112020011345A2 (pt) 2017-12-11 2020-11-17 Tonix Pharma Holdings Limited tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas
EP3840738A1 (en) 2018-08-20 2021-06-30 Tonix Pharma Holdings Limited Methods of treating acute stress disorder and posttraumatic stress disorder
US11337937B2 (en) * 2018-08-27 2022-05-24 ReJoy TARR receptor agonists for sexual dysfunction

Also Published As

Publication number Publication date
WO2021207561A1 (en) 2021-10-14
CN115803088A (zh) 2023-03-14
US20210315841A1 (en) 2021-10-14
EP4132648A1 (en) 2023-02-15
JP2023521167A (ja) 2023-05-23
EP4132648B1 (en) 2026-07-08
JP2025185159A (ja) 2025-12-18
CN115803088B (zh) 2025-03-21
AU2021253592A1 (en) 2022-11-10
JP7780447B2 (ja) 2025-12-04

Similar Documents

Publication Publication Date Title
US20220152057A1 (en) Methods and compositions for treating various disorders
US11707440B2 (en) Esketamine for the treatment of depression
JP2025185159A (ja) 性機能障害のシクロベンザプリン処置
EP4094766A1 (en) Methods of treating uterine fibroids and endometriosis
US20250295674A1 (en) Neuroactive steroids for treatment of cns-related disorders
BRPI0709924A2 (pt) mÉtodo para prevenir ou tratar uma condiÇço decorrente de deficiÊncia de estrogÊnio local
US20220160683A1 (en) Nk-1 antagonist compositions and methods for use in treating depression
US20180280410A1 (en) Natural combination hormone replacement formulations and therapies
JP2023521167A5 (cg-RX-API-DMAC7.html)
WO2023059728A1 (en) Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
EP2758046A1 (en) N- substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders
HK40090080A (zh) 性功能障碍的环苯扎林治疗
HK40090080B (en) Cyclobenzaprine treatment for sexual dysfunction
CN115379843A (zh) 疼痛治疗用药物
US20180369257A1 (en) Selective progesterone receptor modulators (sprm) and stabilized estrogen level in patient
JP2022516482A (ja) うつ病を処置するためのドンペリドン組成物及び方法
US20250090528A1 (en) Use of complement factor d inhibitor for treatment of lupus nephritis and immunoglobulin a nephropathy
CA3218384A1 (en) Use of complement factor d inhibitor for treatment of generalized myasthenia gravis
AU2024238367A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
WO2023159035A1 (en) Neuroactive steroids for treatment of cns-related disorders
AU2024329780A1 (en) Elafibranor for use in the treatment of primary biliary cholangitis
HK40060077A (en) Domperidone compositions and methods for treating depression
HK40103286A (en) Methods of treating conditions related to the s1p₁ receptor

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250331

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250408

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250408

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250408

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250505

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250505

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250505

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250520

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260319

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260319

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260504